1. Introduction {#sec1}
===============

Hidradenitis Suppurativa (HS), also known as Verneuil\'s disease, fox den disease, pyoderma fistulans significa (PFS), or acne inversa, has now been increasingly recognised to be due to a chronic inflammatory recurring skin condition that involves the follicular occlusion of the folliculopilosebaceous units (FPSUs) \[[@B1]\]. HS mainly affects the intertriginous skin areas of the axillary, groin, perianal, perineal, genital, and inframammary skin, as well as other areas of the skin which contains FPSUs. Follicular occlusion, follicular rupture, and the associated innate and adaptive immune dysregulation seem to be the essential events that lead to the development of HS. Bacterial infection and colonization are being regarded as secondary pathogenic factor that may worsen HS. Melnik and Plewig had proposed HS as an autoinflammatory disease characterized by dysregulation of gamma-secretase/Notch pathway \[[@B2]\]. Elevated levels of proinflammatory cytokines such as tumor necrosis factor- (TNF-) *α*, interleukin- (IL-) 1*β*, and IL-17 have been reported in HS lesions. Furthermore, there are also reports on genetic susceptibility, mechanical stresses on the skin, obesity, smoking, and hormonal factors which are closely related to HS \[[@B3]\].

The prevalence of HS is varied and not well described. It ranges from 0.05% to 6%, depending on how and where the data were collected \[[@B4], [@B5]\]. The most recent large population based study involving \>48 million patients in United States found a much higher incidence of 11.4 per 100,000 population \[[@B6]\].

HS has a wide spectrum of clinical manifestation. It ranges from the relatively mild cases characterized by recurrent appearance of papules, pustules, and inflammatory nodules, to severe cases of deep fluctuant abscesses, draining sinuses, and keloidal scars. Although HS is not a life-threatening condition, the pain, foul odour, and disfigurement are associated with significant decrease in quality of life \[[@B7]\]. The diagnosis of HS is made clinically but may be misdiagnosed especially by clinicians who are not familiar with this disease. In case of doubt, a skin biopsy may aid in excluding other diagnoses.

Hurley staging is frequently used to classify patients into 3 disease severity groups:

Stage I: abscess formation (single or multiple) without sinus tracts and scaring

Stage II: recurrent abscesses with sinus tracts and scarring, single, or multiple widely separated lesions

Stage III: diffuse or almost diffuse involvement, or multiple interconnected sinus tracts and abscesses across the entire area

HS is notoriously difficult to treat as it has multiple presentation and runs an unpredictable course. Treatment is based on disease severity, presence of comorbidities, patients\' tolerance and preferability to the treatment, treatment cost, and the availability of treatment options. Besides the usual topical antibiotics and antiseptics dressings, there are systemic antibiotics, retinoids, and hormonal therapy. Recent evidence has shown that adalimumab and infliximab, 2 different monoclonal antibodies against TNF-*α*, are effective in the treatment of moderate to severe HS. Adalimumab is the first Food and Drug Administration (FDA) approved treatment for moderate to severe HS in adults. The European Medicine Agency has also recently accepted HS as an indication for adalimumab. In 2015, the Board of the Italian Society of Dermatology and Venereology (SIDeMaST) has also given out guidelines on the role of TNF-*α* inhibitors in the management of HS \[[@B8]\]. Other trial drugs, such as IL-1 receptor antagonist (anakinra) and Human IgG kappa monoclonal antibody to IL-1*β* (canakinumab), have also shown improvement in HS \[[@B9], [@B10]\]. Above all, patient education and psychological support play an important role in managing HS.

This study aims to identify the demographic and clinical characteristics and treatment modalities in patients with HS in Hospital Kuala Lumpur (HKL). We also compare the clinical characteristics of HS patients of different ethnicity and gender group.

2. Materials and Methods {#sec2}
========================

This was a retrospective study involving all patients who had been clinically diagnosed with Hidradenitis Suppurativa from 1 July 2009 to 30 June 2016 in Dermatology Clinic, Kuala Lumpur Hospital. Based on the electronic record from the clinic registration, all of the clinic notes of these patients with the diagnosis of HS were traced and reviewed by 3 doctors from the clinic who had been trained to collect the data. Information such as the demographic information, clinical characteristics, and treatment modalities were extracted from patients\' clinic notes and transcribed into the data collection form.

The collected data were analyzed using SPSS 22.0. Descriptive data were performed. All categorical variables such as gender and ethnicity, clinical characteristics, and treatment modalities were summarized as numbers and percentage, while continuous variables such as current age, age at diagnosis, and duration of illness before diagnosis were calculated and expressed in median and interquartile range (IQR). Assumption of normality was based on Kolmogorov-Smirnov statistics, skewness, kurtosis, histograms, and Q-Q plots. The majority of our continuous variables were not normally distributed; therefore, nonparametric tests were used for further data analysis. The tests used were chi-square test for independence, Fisher\'s exact test, and Mann--Whitney *U* test. A 2-tailed *p* value of \<0.05 is considered as statistically significant.

3. Results {#sec3}
==========

Of the 47067 records of new cases registered in HKL Dermatology Clinic from 1 July 2009 to 30 June 2016, a total of 62 patients were identified to have the diagnosis of HS. This led to an incidence rate of 0.013 per 100,000 clinic population. An equal number of cases were seen between females and males. HS were seen in patients between 14 and 79 years old. The median age at diagnosis was 25 (IQR: 14) years. Male patients were noted to be diagnosed at an older age (median age: 33, IQR 16 years old) when compared to female patients (median age: 24, IQR: 12 years old, *p* = 0.006). There was no significant difference between both genders in the duration of illness before being diagnosed with HS (*p* = 0.101).

[Table 1](#tab1){ref-type="table"} shows the demographic characteristics of patients with HS according to gender, ethnicity, age at diagnosis, and duration of illness before diagnosis. HS was more frequently seen in Malay (41.9%), followed by Indian (35.5%), Chinese (17.7%), and other ethnicities (4.8%). There was a delay in making the diagnosis with median duration of illness prior to diagnosis of 24 (IQR: 52) months, with the longest duration of 30 years. There were only 2 patients with similar family history of HS. Nine patients were cigarette smokers. Median BMI of our patients was 34.0 (IQR 20.2), calculated with missing data of up to 90%.

[Table 2](#tab2){ref-type="table"} shows the clinical characteristics of our study cohort. Majority of the patients had lesions over the axilla (85.5%), followed by groin (33.9%) and gluteal region (29%). Male patients had significant lesions over the gluteal region (*p* = 0.002) ([Table 5](#tab5){ref-type="table"}).

The types of lesions commonly seen were nodules (67.7%), sinuses (56.5%), pustules (37.1%), keloid scar (35.5%), and abscesses (33.9%). More than half of them (56.5%) reported symptoms of pain, while a third (37.1%) reported pruritus. There was no significant difference detected in the type of lesions, severity, and symptoms of HS, in between different ethnicities, as well as between male and female patients (Tables [5](#tab5){ref-type="table"} and [6](#tab6){ref-type="table"})

About 35.5% of patients had positive swab or tissue culture, which grew a mixture of Gram-positive and Gram-negative organisms ([Table 3](#tab3){ref-type="table"}).

In terms of treatment modalities, more than 75% of the patients had topical treatment, which include topical fusidic acid (30.6%), mupirocin (8.1%), clindamycin (4.8%), and antiseptic wash such as chlorhexidine, prontosan, and octenisan wash (66.1%). Fifty-two patients had received systemic antibiotics such as doxycycline (29%), rifampicin (29%), clindamycin (21.1%), tetracycline (8.1%), metronidazole (6.5%), and minocycline (1.6%). Thirty patients had isotretinoin while only 6 patients had acitretin. Six patients had dapsone for the treatment of HS. None of these patients had biologics. A third of these patients had some surgical intervention, which include incision and drainage (14 patients), localised excision (6 patients), and wide local excision and skin graft (3 patients). [Figure 1](#fig1){ref-type="fig"} shows the treatment modalities of patients with HS.

[Table 4](#tab4){ref-type="table"} shows the comorbidities of the patients with HS. Seventeen patients (27.4%) had Acne Conglobata or Nodulocystic Acne. Pilonidal sinus was diagnosed in 3 patients. None of these patients fulfilled the criteria of the follicular occlusion triad or tetrad, only 9 patients (14.5%) with obesity, 6 patients (9.7%) with diabetes mellitus, and 4 (6.5%) with hypertension and dyslipidemia. One patient had concurrent HIV and hepatitis C infection. Depression was also detected in 1 patient with HS. In [Table 6](#tab6){ref-type="table"}, HS patients with concurrent hypertension and dyslipidemia are seen more in the Chinese population (*p* = 0.039, *p* = 0.031 consecutively).

4. Discussion {#sec4}
=============

Sixty-two patients had the diagnosis of HS from the review of medical records from 1 July 2009 to 30 June 2016. This has shown an increasing trend when we compare to a similar study done by Leelavathi et al. which reported only 15 patients over 5-year period \[[@B11]\] ([Table 7](#tab7){ref-type="table"}).

Many studies reported that HS is a rarely diagnosed disease \[[@B4], [@B12], [@B13]\]. Vazquez et al. reported that only 268 patients were diagnosed with HS in Minnesota between 1968 and 2008, with an overall annual age- and sex-adjusted incidence of 6.0 per 100,000. Cosmatos et al. found a low rate of clinically detected HS where the overall prevalence estimate was 0.053% in a retrospective analysis using health insurance database in the United States ([Table 7](#tab7){ref-type="table"}). We found an incidence rate of 0.013 in 100,000 clinic population, which is much lower than previous studies. This is because Hospital Kuala Lumpur, being a fully subsidized government hospital, is a major tertiary center in Malaysia. Although primarily covering Kuala Lumpur and its surrounding area, it also has patients coming from other parts of the country, including almost the whole of Peninsular Malaysia.

We noted that the ratio of male to female patients was equal, which is inconsistent with previous studies \[[@B4], [@B5], [@B13]--[@B15]\]. Our number of male to female patients visits to dermatology clinic during this study period was almost equal (1 : 0.94). Shali Alikhan et al. reported that women outnumbered men with HS by nearly 3 to 1, and Garg et al. reported that prevalence of female patients was more than 2-fold greater than in male patients. The only study that reported an obvious male predominant in HS was seen in a study in Tunisia \[[@B16]\].

In our study, the median age at diagnosis was 25 (IQR: 14) years. Male patients with HS were found to be significantly older at the time of diagnosis compared to female patients, with median age of 33, IQR 16 years old for males, compared to median age of 24, IQR 12 years old for females, with *p* = 0.006. This is in line with a study in Minnesota which found that the highest incidence of HS is among young women aged 20--29 (18.4 per 100,000) \[[@B4]\]. Cosmatos et al. \[[@B13]\] found that most patients with HS were aged 30 to 64 years ([Table 7](#tab7){ref-type="table"}).

The diagnosis of HS is often delayed. This is due to the fact that HS has a wide spectrum of manifestation and may mimic other illnesses and commonly treated as skin infections such as recurrent furuncles. This delay may be caused by patient delay in seeking treatment, the clinician not making the correct diagnosis, or both. The longest duration of diagnosis after the onset of symptoms in this study was 30 years. This patient had gone to multiple primary care physicians who had failed to give the accurate diagnosis. We also had a patient who had underwent several surgical interventions to the abscesses and only later diagnosed with HS. This finding is in line with previous studies, which reported significant delay in the diagnosis of HS \[[@B4], [@B17]\].

It was also surprising to see that, in our study, the proportion of Indians diagnosed with HS was much higher (35.5%) when compared with the number of new cases of Indian patients during the study period (18.1%). A study by McMillan in 2014 reported that the percentage of visits with HS diagnosis in black patients was significantly higher than the percentage of all visits by black patients in a combined data from the National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) in the United States \[[@B12]\]. In another study, the adjusted HS prevalence among African American patients with HS was more than 3-fold than that among white patients \[[@B15]\]. An increased frequency of HS is observed in blacks, possibly because blacks have a greater density of apocrine glands than whites. This same explanation can be postulated in our finding associating HS with the Indian ethnicity in Malaysia, who has darker Fitzpatrick phototype as compared to other ethnicities such as Malay and Chinese.

Although there are emerging data on the association of obesity, metabolic syndrome, and other related comorbidities with HS \[[@B18]--[@B20]\], we did not find significant difference statistically between obesity and metabolic syndrome with HS. This is due to the limited documentation in our retrospective study. Missing data were up to 90% in certain categories, as they were not documented in patients\' record.

However, with the limited data, we noted that Chinese patients had significantly higher percentage of having concurrent hypertension and dyslipidemia, but there was no difference of comorbidities in between males and females. With the combination of smoking in patients with HS, these contribute to a higher risk of cardiovascular-associated death, as shown in Danish HS patients \[[@B21]\]. None of our patients reported having inflammatory bowel disease or rheumatology condition, as described previously. Previous studies have found that patients with HS have a higher risk of developing depression \[[@B22]\]. In our study, only 1 patient had been diagnosed with depression and currently being treated by the psychiatry team. The low prevalence of depression may be due to the fact that psychiatry illness is still a taboo in our country and therefore patients do not openly express their emotional distress to the clinician.

Majority of the patients had lesions over the axilla, followed by groin and gluteal region, inframammary, chest, back, neck, and postauricular region. The lesions were composed of nodules, sinuses, pustules, keloid scar, and abscesses. At diagnosis, majority of the patients had moderate to severe symptoms (Hurley stages 2 and 3) and more than half of them reported symptoms of pain, while a third reported pruritus. Previous studies had reported that the distribution of lesions in HS is influence by gender. Primary sites of involvement in females are the groin or upper inner thigh, axilla, upper anterior torso (including breast and inframammary regions), and the buttocks or gluteal clefts \[[@B4], [@B23]\]. In males, the common sites are the groin or thigh, axilla, perineal or perianal regions, and buttocks or gluteal cleft \[[@B24]\]. However, when comparing between males and females in our patients with HS, there was no significant difference between the severity, symptoms of HS, or the location of lesions, except that male patients had more significant lesions over the gluteal region.

Although routine bacterial culture is not indicated, we noted that patients with secondary bacterial infection worsened HS condition. In this study, the swab and/or tissue culture grew mixture of Gram-positive and Gram-negative organism, which can aid in the choice of antibiotics for these patients.

The most common oral tetracycline regime in our clinic is doxycycline, given in the highest percentage of patients, at the dosage of 100 mg once to twice daily. This is the key treatment for mild to moderate HS with favourable adverse effect profile. Combination therapy with clindamycin and rifampicin is the next option, usually to those who have failed oral tetracycline. Our regimen of combination therapy is clindamycin 300 mg twice daily and rifampicin 300 mg twice daily. Previous studies have shown that 35%--70% of patients had at least some improvement in their disease course, with sustained efficacy of more than 40% in 1 year \[[@B25]--[@B27]\].

Besides systemic antibiotics, more than half of our cohort received oral retinoid. Most of these patients were on isotretinoin, especially those with concurrent nodulocystic acne. Studies involving acitretin treatment have reported significant improvements in up to 60% of patients \[[@B27]\]. It is also more effective when used as an adjuvant to other systemic medications. Surgical interventions were also treatment choice for those with recurrent and complicated HS.

Although recent studies have shown that monoclonal antibodies against TNF-*α* are effective in moderate to severe HS, none of our patients had yet to receive biologic treatment \[[@B28]\]. This is due to our limited financial resources in this fully funded government clinic. Perhaps when the generic version of biologics or "biosimilars" is widely available, and cost is not an issue anymore, more patients would be on biologic treatment especially those with recalcitrant HS.

We had difficulty in ascertaining the outcome of treatment, as most of them had received multiple treatment modalities in their course of management. Furthermore, we noted that about half of these patients had defaulted on their appointment. This is the limitation that needs to be addressed as this study relied on previous documentations on patients\' medical record. In addition, our result may have limited generalizability, as the population size is very small. Therefore, a larger, prospective cohort study is recommended to look specifically at the treatment modalities and the outcome of each treatment in the near future.

5. Conclusion {#sec5}
=============

In conclusion, there is an equal gender distribution in our HS patients, with higher proportion in Indian population. Most of our patients were young adults, with a median age of diagnosis of 25 years, with long delay in the diagnosis of HS. Thus, it is pertinent that clinicians should be able to make an accurate diagnosis with comprehensive clinical examination, to screen for the associated comorbidities and to initiate treatment early to avoid the physical and emotional complications of this debilitating chronic skin disease.
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###### 

Demographic characteristics of patients with HS.

  Characteristics                                 *n* (%)     Median (IQR)
  ----------------------------------------------- ----------- --------------
  Gender                                                       
   Male                                           31 (50)      
   Female                                         31 (50)      
  Ethnicity                                                    
   Malay                                          26 (41.9)    
   Indian                                         22 (35.5)    
   Chinese                                        11 (17.7)    
   Others                                         3 (4.8)      
  Current age (years old)                                     31.5 (14)
  Age at diagnosis (years old)                                25.0 (14)
  Duration of illness before diagnosis (months)               24.0 (52)

###### 

Clinical characteristics of patients with HS.

  Characteristics     *n* (%)
  ------------------- -----------
  Types of lesions     
   Nodules            42 (67.7)
   Sinus              35 (56.5)
   Pustules           23 (37.1)
   Keloid scar        22 (35.5)
   Abscess            21 (33.9)
   Double comedones   2 (3.2)
   Fistula            2 (3.2)
  Location             
   Axilla             53 (85.5)
   Groin              21 (33.9)
   Gluteal            18 (29)
   Chest              10 (16.1)
   Back               9 (14.5)
   Neck               8 (12.9)
   Inframammary       4 (6.5)
   Genitalia          2 (3.2)
   Postauricular      1 (1.6)
  Hurley staging       
   1                  22 (35.5)
   2                  27 (43.5)
   3                  13 (21)
  Symptoms             
   Pain               35 (56.5)
   Pruritus           23 (37.1)
   Embarrassment      12 (19.4)

###### 

Cultures taken from patients with HS.

  Bacteriological culture (swab or tissue)   Number (%)
  ------------------------------------------ ------------
  Gram-positive                               
   *Staphylococcus*                          7 (11.3)
   MSSA                                      4 (6.5)
   MRSA                                      3 (4.8)
   GBS                                       4 (6.5)
   *Streptococcus pyogenes*                  1 (1.6)
    Diphtheroids                             4 (6.5)
   *Enterococcus*                            1 (1.6)
  Gram-negative                               
   *E. coli*                                 6 (9.7)
   *Proteus* sp.                             5 (8.1)
   *Klebsiella pneumonia*                    4 (6.5)
   *Acinetobacter*                           2 (3.2)
  Mixed growth                               7 (11.3)
  Others                                      
   *Chrysosporium* sp.                       1 (1.6)

MSSA: Methicillin Sensitive *Staphylococcus aureus*, MRSA: Methicillin Resistant *Staphylococcus aureus*, and GBS: Group B *Streptococcus*.

###### 

Comorbidities in patients with HS.

  Comorbidities                  Number (%)
  ------------------------------ ------------
  Acne conglobata/nodulocystic   17 (27.4)
  Obesity                        9 (14.5)
  Diabetes                       6 (9.7)
  Hypertension                   4 (6.5)
  Dyslipidemia                   4 (6.5)
  Pilonidal sinus                3 (4.8)
  Anemia                         3 (4.8)
  Neoplasm (SCC)                 1 (1.6)
  RVD and hepatitis C            1 (1.6)
  Depression                     1 (1.6)

###### 

Comparison of HS clinical characteristics between male and female patients with HS.

  -----------------------------------------------------------------------------------------------
  Clinical characteristics                Male (*n* = 31)  \   Female (*n* = 31)  \   *p* value
                                          *n* (%)              *n* (%)                
  --------------------------------------- -------------------- ---------------------- -----------
  *Severity of HS*                                                                     

  Mild (Hurley stage 1)                   8 (25.8)             14 (45.2)              0.111

  Moderate to severe (Hurley stage 2-3)   23 (74.2)            17 (54.8)              

  *Symptoms*                                                                           

  Embarrassment                           4 (12.9)             0 (0)                  0.113

  Pain                                    18 (58.1)            17 (54.8)              0.798

  Pruritus                                11 (35.5)            12 (38.7)              0.793

  *Location of lesion*                                                                 

  Axilla                                  25 (80.6)            28 (90.3)              0.279

  Groin                                   9 (29.0)             12 (38.7)              0.421

  Gluteal                                 15 (48.4)            3 (9.7)                0.002

  Chest                                   4 (12.9)             6 (19.4)               0.490

  Back                                    7 (22.6)             2 (6.5)                0.071

  Neck                                    2 (6.5)              6 (19.4)               0.130

  Inframammary                            2 (6.5)              2 (6.5)                1.000

  Genitalia                               1 (3.2)              1 (3.2)                1.000

  Postauricular                           1 (3.2)              0 (0)                  0.313

  *Types of lesion*                                                                    

  Papules                                 8 (25.8)             7 (22.6)               0.767

  Nodules                                 22 (71.0)            20 (64.5)              0.587

  Sinus                                   19 (61.3)            16 (51.6)              0.442

  Pustules                                12 (38.7)            11 (35.5)              0.793

  Keloid scar                             13 (41.9)            9 (29.0)               0.288

  Abscess                                 12 (38.7)            9 (29.0)               0.421

  Double comedones                        1 (3.2)              1 (3.2)                1.000

  Fistula                                 1 (3.2)              1 (3.2)                1.000

  *Comorbidities*                                                                      

  Nodulocystic acne                       9 (29.0)             8 (25.8)               0.776

  Obesity                                 4 (12.9)             5 (16.1)               0.718

  Diabetes                                4 (12.9)             2 (6.5)                0.671

  Hypertension                            3 (9.7)              1 (3.2)                0.612

  Dyslipidemia                            2 (6.5)              2 (6.5)                1.000
  -----------------------------------------------------------------------------------------------

###### 

Comparison of clinical characteristics of HS among different ethnicity group.

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Clinical characteristics       Malay (*n* = 26)  \   Chinese (*n* = 11)  \   Indian (*n* = 22)  \   Others (*n* = 3)  \   Total (*n* = 62)   *p* value
                                 *n* (%)               *n* (%)                 *n* (%)                *n* (%)                                  
  ------------------------------ --------------------- ----------------------- ---------------------- --------------------- ------------------ -----------
  *Severity of HS*                                                                                                                              

  Mild                           9 (34.6)              3 (27.3)                9 (40.9)               1 (33.3)              22 (35.5)          0.892

  Moderate-severe                17 (65.4)             8 (72.7)                13 (59.1)              2 (66.7)              40 (64.5)          

  *Symptoms*                                                                                                                                    

  Pain                           14 (53.8)             4 (36.4)                15 (68.2)              2 (66.7)              35 (56.5)          0.357

  Pruritus                       8 (30.8)              3 (27.3)                10 (45.5)              2 (66.7)              23 (37.1)          0.443

  Embarrassment                  1 (3.8)               1 (9.1)                 1 (4.5)                1 (33.3)              12 (19.4)          0.246

  *Location of lesion*                                                                                                                          

  Axilla                         23 (88.5)             6 (54.5)                21 (95.5)              3 (100)               53 (85.5)          0.022

  Groin                          7 (26.9)              6 (54.5)                7 (31.8)               1 (33.3)              21 (33.9)          0.440

  Gluteal                        6 (23.1)              7 (63.6)                5 (22.7)               0 (0)                 18 (29)            0.061

  Chest                          5 (19.2)              0 (0)                   5 (22.7)               0 (0)                 10 (16.1)          0.310

  Back                           4 (15.4)              4 (36.4)                1 (4.5)                0 (0)                 9 (14.5)           0.089

  Neck                           4 (15.4)              2 (18.2)                2 (9.1)                0 (0)                 8 (12.9)           0.766

  Inframammary                   3 (11.5)              0 (0)                   0 (0)                  1 (33.3)              4 (6.5)            0.072

  Genitalia                      1 (3.8)               0 (0)                   1 (4.5)                0 (0)                 2 (3.2)            0.892

  Postauricular                  1 (3.8)               0 (0)                   0 (0)                  0 (0)                 1 (1.6)            0.704

  *Types of lesion*                                                                                                                             

  Nodules                        18 (69.2)             8 (72.7)                15 (68.2)              1 (33.3)              42 (67.7)          0.620

  Sinus                          14 (53.8)             8 (72.7)                11 (50.0)              2 (66.7)              35 (56.5)          0.624

  Pustules                       6 (23.1)              6 (54.5)                9 (40.9)               2 (66.7)              23 (37.1)          0.180

  Keloid scar                    9 (34.6)              6 (54.5)                7 (31.8)               0 (0)                 22 (35.5)          0.316

  Abscess                        7 (26.9)              4 (36.4)                8 (36.4)               2 (66.7)              21 (33.9)          0.553

  Double comedones               0 (0)                 0 (0)                   1 (4.5)                1 (33.3)              2 (3.2)            0.083

  Fistula                        2 (7.7)               0 (0)                   0 (0)                  0 (0)                 2 (3.2)            0.413

  *Comorbidities*                                                                                                                               

  Acne conglobata/nodulocystic   8 (30.8)              3 (27.3)                6 (27.3)               0 (0)                 17 (27.4)          0.734

  Obesity                        5 (19.2)              1 (9.1)                 3 (13.6)               0 (0)                 9 (14.5)           0.741

  Diabetes                       3 (11.5)              2 (18.2)                0 (0)                  1 (33.3)              6 (9.7)            0.152

  Hypertension                   1 (3.8)               3 (27.3)                0 (0)                  0 (0)                 4 (6.5)            0.039

  Dyslipidemia                   1 (3.8)               2 (18.2)                0 (0)                  1 (33.3)              4 (6.5)            0.031
  --------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Comparison between our study cohort and previous studies.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variables                                       Vazquez et al., 2013             Cosmatos et al., 2013         Vinding et al., 2014               Leelavathi et al., 2009          Our study
  ----------------------------------------------- -------------------------------- ----------------------------- ---------------------------------- -------------------------------- -----------------------------------------------
  Country                                         Minnesota, USA                   USA                           Copenhagen, Denmark                HKL                              HKL

  Year                                            1968--2008                       2007                          2014                               2002--2006                       2009--2016

  Study type                                      Retrospective, medical records   Registry, insurers database   Self-administered questionnaires   Retrospective, medical records   Retrospective, medical records

  Number of cases                                 268 cases\                       0.053%\                       2.10%,\                            15 cases                         62 cases\
                                                  6.0/100,000 (incidence)          (7927/144,000) (prevalence)   (Total patients 16404)\                                             0.013/100,000 hospital population (incidence)
                                                                                                                 (prevalence)                                                        

  Age at diagnosis                                Median 30.6 years (9.9--78.5)    Mean 38.2 (14.73) years                                          Mean 27.8 years\                 Median 25.0 (12--69) years
                                                                                                                                                    (21--30)                         

  Gender F : M                                    2.2 : 1                          3 : 1                         1.6 : 1                            2.8 : 1                          1 : 1

  Duration between onset of symptom & diagnosis   3.3 years  \                     \-                            \-                                 \-                               24 months\
                                                  (0 to 30 years)                                                                                                                    (1 to 360 months)

  Obesity                                         54.9%                                                          72.9%                              13.3%\                           9 patients (14.5%)\
                                                                                                                                                    (33% missing data)               (up to 90% missing data)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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